{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:02:26Z","timestamp":1789322546142,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971240"],"award-info":[{"award-number":["31971240"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271364"],"award-info":[{"award-number":["32271364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115683","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T02:18:01Z","timestamp":1690337881000},"page":"115683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["RIPK2 inhibitors for disease therapy: Current status and perspectives"],"prefix":"10.1016","volume":"259","author":[{"given":"Erkang","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115683_bib1","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.4049\/jimmunol.1502631","article-title":"Synthetic biology reveals the uniqueness of the RIP kinase domain","volume":"196","author":"Chirieleison","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115683_bib2","doi-asserted-by":"crossref","unstructured":"J. Bertin, W.-J. Nir, C.M. Fischer, O.V. Tayber, P.R. Errada, J.R. Grant, J.J. Keilty, M.L. Gosselin, K.E. Robison, G.H.W. Wong, M.A. Glucksmann, P.S. DiStefano, Human CARD4 protein is a novel CED-4\/apaf-1 cell death family member that activates NF-\u03baB, J. Biol. Chem. 274 (1999) 12955\u201312958. https:\/\/doi.org\/10\/b9xjsc.","DOI":"10.1074\/jbc.274.19.12955"},{"key":"10.1016\/j.ejmech.2023.115683_bib3","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1126\/science.1084677","article-title":"Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan","volume":"300","author":"Girardin","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115683_bib4","doi-asserted-by":"crossref","first-page":"14739","DOI":"10.1073\/pnas.1003363107","article-title":"Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum","volume":"107","author":"Biswas","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115683_bib5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1183\/09031936.00010209","article-title":"CARD15\/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis","volume":"35","author":"Sato","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2023.115683_bib6","first-page":"2948","article-title":"Nucleotide-binding oligomerization domain 2 signaling promotes hyperresponsive macrophages and colitis in IL-10-deficient mice","volume":"190","author":"Jamontt","year":"2013","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"10.1016\/j.ejmech.2023.115683_bib7","first-page":"129","article-title":"Inhibition of RIP2\/RICK\/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK, Mol. Cell","volume":"268","author":"Argast","year":"2005","journal-title":"Biochemist"},{"key":"10.1016\/j.ejmech.2023.115683_bib8","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1101\/gad.1964410","article-title":"Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses","volume":"24","author":"Tigno-Aranjuez","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2023.115683_bib9","doi-asserted-by":"crossref","first-page":"29651","DOI":"10.1074\/jbc.M114.591388","article-title":"In vivo inhibition of RIPK2 kinase alleviates inflammatory disease","volume":"289","author":"Tigno-Aranjuez","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib10","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1038\/ncomms7442","article-title":"A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production","volume":"6","author":"Nachbur","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115683_bib11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.chembiol.2015.07.017","article-title":"Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors","volume":"22","author":"Canning","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115683_bib12","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1021\/acs.jmedchem.6b00211","article-title":"The identification and pharmacological characterization of 6-(tert -butylsulfonyl)- N -(5-fluoro-1 H -indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase","volume":"59","author":"Haile","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112417","article-title":"Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold","volume":"200","author":"Suebsuwong","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1127722","article-title":"Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases","volume":"14","author":"Pham","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115683_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1192970","article-title":"RIPK2: a promising target for cancer treatment","volume":"14","author":"You","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115683_bib16","doi-asserted-by":"crossref","unstructured":"J.V. McCarthy, J. Ni, V.M. Dixit, RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase, J. Biol. Chem. 273 (1998) 16968\u201316975. https:\/\/doi.org\/10\/c2mv3b.","DOI":"10.1074\/jbc.273.27.16968"},{"key":"10.1016\/j.ejmech.2023.115683_bib17","doi-asserted-by":"crossref","first-page":"27823","DOI":"10.1074\/jbc.M003415200","article-title":"An induced proximity model for NF-kappa B activation in the Nod1\/RICK and RIP signaling pathways","volume":"275","author":"Inohara","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib18","doi-asserted-by":"crossref","first-page":"19183","DOI":"10.1074\/jbc.M109.006353","article-title":"The kinase activity of Rip2 determines its stability and consequently Nod1- and Nod2-mediated immune responses","volume":"284","author":"Nembrini","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib19","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1038\/s41467-018-07447-9","article-title":"Structural basis of RIP2 activation and signaling","volume":"9","author":"Gong","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115683_bib20","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.4049\/jimmunol.1600258","article-title":"Dual inhibition of Rip2 and IRAK1\/4 regulates IL-1\u03b2 and IL-6 in sarcoidosis alveolar macrophages and peripheral blood mononuclear cells","volume":"197","author":"Talreja","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115683_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coviro.2015.04.004","article-title":"How RIG-I like receptors activate MAVS","volume":"12","author":"Wu","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejmech.2023.115683_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.650403","article-title":"RIPK2 as a new therapeutic target in inflammatory bowel diseases","volume":"12","author":"Honjo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115683_bib23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1124\/jpet.117.247163","article-title":"Identification and characterization of novel receptor-interacting serine\/threonine-protein kinase 2 inhibitors using structural similarity analysis","volume":"365","author":"Salla","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115683_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11010-009-0309-9","article-title":"MS80, a novel sulfated polysaccharide, inhibits CD40-NF-kappaB pathway via targeting RIP2","volume":"337","author":"Du","year":"2010","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2023.115683_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113252","article-title":"Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling","volume":"215","author":"Nikhar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20061704","article-title":"Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide","volume":"404","author":"Windheim","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2023.115683_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022356","article-title":"cIAP1\/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4)","volume":"6","author":"Bertrand","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115683_bib28","doi-asserted-by":"crossref","first-page":"16968","DOI":"10.1074\/jbc.273.27.16968","article-title":"RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase","volume":"273","author":"McCarthy","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib29","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1073\/pnas.2534856100","article-title":"Fundamental role of the Rip2\/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death","volume":"100","author":"Zhang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115683_bib30","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1523\/JNEUROSCI.21-16-05854.2001","article-title":"A prosurvival function for the p75 receptor death domain mediated via the caspase recruitment domain receptor-interacting protein 2","volume":"21","author":"Khursigara","year":"2001","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115683_bib31","doi-asserted-by":"crossref","unstructured":"K.A. Archer, F. Ader, K.S. Kobayashi, R.A. Flavell, C.R. Roy, Cooperation between multiple microbial pattern recognition systems is important for host protection against the intracellular pathogen Legionella pneumophila, Infect. Immun. 78 (2010) 2477\u20132487. https:\/\/doi.org\/10\/cs7ctp.","DOI":"10.1128\/IAI.00243-10"},{"key":"10.1016\/j.ejmech.2023.115683_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.chom.2008.12.011","article-title":"Shigella induces mitochondrial dysfunction and cell death in nonmyleoid cells","volume":"5","author":"Carneiro","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2023.115683_bib33","doi-asserted-by":"crossref","first-page":"9642","DOI":"10.1074\/jbc.M312893200","article-title":"RICK activates a NF-kappaB-dependent anti-human cytomegalovirus response","volume":"279","author":"Eickhoff","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib34","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1073\/pnas.0907131106","article-title":"XIAP mediates NOD signaling via interaction with RIP2","volume":"106","author":"Krieg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115683_bib35","doi-asserted-by":"crossref","unstructured":"Y. Hu, B. Jiao, C. Wang, J. Wu, Regulation of temozolomide resistance in glioma cells via the RIP2\/NF\u2010\u03baB\/MGMT pathway, CNS Neurosci. Therapy. 27 (2021) 552\u2013563. https:\/\/doi.org\/10\/grz684.","DOI":"10.1111\/cns.13591"},{"key":"10.1016\/j.ejmech.2023.115683_bib36","doi-asserted-by":"crossref","unstructured":"S.M. Singel, K. Batten, C. Cornelius, G. Jia, G. Fasciani, S.L. Barron, W.E. Wright, J.W. Shay, Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways, Breast Cancer Res.. 16 (2014) R28. https:\/\/doi.org\/10\/f59d4s.","DOI":"10.1186\/bcr3629"},{"key":"10.1016\/j.ejmech.2023.115683_bib37","doi-asserted-by":"crossref","unstructured":"Y. Shen, H. Lin, K. Chen, W. Ge, D. Xia, Y. Wu, W. Lu, High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer, J. Ovarian Res. 15 (2022) 48. https:\/\/doi.org\/10\/gp2gm9.","DOI":"10.1186\/s13048-022-00986-2"},{"key":"10.1016\/j.ejmech.2023.115683_bib38","doi-asserted-by":"crossref","first-page":"10450","DOI":"10.18632\/aging.202808","article-title":"RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma","volume":"13","author":"Li","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.ejmech.2023.115683_bib39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12974-020-02015-9","article-title":"NOD1\/RIP2 signalling enhances the microglia-driven inflammatory response and undergoes crosstalk with inflammatory cytokines to exacerbate brain damage following intracerebral haemorrhage in mice","volume":"17","author":"Wang","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2023.115683_bib40","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1161\/CIRCULATIONAHA.119.041213","article-title":"Innate immune nod1\/RIP2 signaling is essential for cardiac hypertrophy but requires mitochondrial antiviral signaling protein for signal transductions and energy balance","volume":"142","author":"Lin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2023.115683_bib41","doi-asserted-by":"crossref","unstructured":"P.J. Shaw, M.J. Barr, J.R. Lukens, M.A. McGargill, H. Chi, T.W. Mak, T.-D. Kanneganti, Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity, Immunity. 34 (2011) 75\u201384. https:\/\/doi.org\/10\/dzxjz6.","DOI":"10.1016\/j.immuni.2010.12.015"},{"key":"10.1016\/j.ejmech.2023.115683_bib42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.phrs.2018.10.016","article-title":"Gene silencing of receptor-interacting protein 2 protects against cigarette smoke-induced acute lung injury","volume":"139","author":"Dong","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115683_bib43","doi-asserted-by":"crossref","first-page":"14981","DOI":"10.1074\/jbc.M500966200","article-title":"Inhibition of RICK\/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease","volume":"280","author":"Hollenbach","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib44","doi-asserted-by":"crossref","unstructured":"Z. Xu, D. Li, W. Qu, Y. Yin, S. Qiao, Y. Zhu, S. Shen, Y. Hou, J. Yang, T. Wang, Card9 protects sepsis by regulating Ripk2-mediated activation of NLRP3 inflammasome in macrophages, Cell Death Dis.. 13 (2022) 502. https:\/\/doi.org\/10\/grz7cg.","DOI":"10.1038\/s41419-022-04938-y"},{"key":"10.1016\/j.ejmech.2023.115683_bib45","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa086","article-title":"RIPK2 dictates insulin responses to tyrosine kinase inhibitors in obese male mice","volume":"161","author":"Duggan","year":"2020","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2023.115683_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetmic.2020.108896","article-title":"Prolonged exposure to high humidity and high temperature environment can aggravate influenza virus infection through intestinal flora and Nod\/RIP2\/NF-\u03baB signaling pathway","volume":"251","author":"Deng","year":"2020","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115683_bib47","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/0022034512454541","article-title":"ASC-dependent RIP2 kinase regulates reduced PGE2 production in chronic periodontitis","volume":"91","author":"Taxman","year":"2012","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.ejmech.2023.115683_bib48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2022.01.014","article-title":"Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1\/RIPK2\/NF-\u03baB pathway","volume":"530","author":"Nomoto","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2023.115683_bib49","doi-asserted-by":"crossref","unstructured":"Y. Zhang, A. Cook, J. Kim, S.V. Baranov, J. Jiang, K. Smith, K. Cormier, E. Bennett, R.P. Browser, A.L. Day, D.L. Carlisle, R.J. Ferrante, X. Wang, R.M. Friedlander, Melatonin inhibits the caspase-1\/cytochrome c\/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis, Neurobiol. Dis. 55 (2013) 26\u201335. https:\/\/doi.org\/10\/f4x52s.","DOI":"10.1016\/j.nbd.2013.03.008"},{"key":"10.1016\/j.ejmech.2023.115683_bib50","doi-asserted-by":"crossref","unstructured":"L. Andersson, M. Scharin T\u00e4ng, A. Lundqvist, M. Lindbom, I. Mardani, P. Fogelstrand, P. Shahrouki, B. Redfors, E. Omerovic, M. Levin, J. Bor\u00e9n, M.C. Levin, Rip2 modifies VEGF-induced signalling and vascular permeability in myocardial ischaemia, Cardiovasc. Res. 107 (2015) 478\u2013486. https:\/\/doi.org\/10\/f3m4cw.","DOI":"10.1093\/cvr\/cvv186"},{"key":"10.1016\/j.ejmech.2023.115683_bib51","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.3390\/cells11142241","article-title":"Muramyl dipeptide administration delays alzheimer's disease physiopathology via NOD2 receptors","volume":"11","author":"Piec","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115683_bib52","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1073\/pnas.0508888102","article-title":"Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors","volume":"102","author":"Gurova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115683_bib53","doi-asserted-by":"crossref","unstructured":"F. Humphries, S. Yang, B. Wang, P.N. Moynagh, RIP kinases: key decision makers in cell death and innate immunity, Cell Death Differ.. 22 (2015) 225\u2013236. https:\/\/doi.org\/10\/f6wmzr.","DOI":"10.1038\/cdd.2014.126"},{"key":"10.1016\/j.ejmech.2023.115683_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115683_bib55","doi-asserted-by":"crossref","first-page":"10450","DOI":"10.18632\/aging.202808","article-title":"RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma","volume":"13","author":"Li","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.ejmech.2023.115683_bib56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1083\/jcb.201608024","article-title":"VHL promotes immune response against renal cell carcinoma via NF-\u03baB-dependent regulation of VCAM-1","volume":"216","author":"Labrousse-Arias","year":"2017","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115683_bib57","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1073\/pnas.1816626116","article-title":"A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer","volume":"116","author":"Lucki","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115683_bib58","first-page":"1677","article-title":"NOD1, RIP2 and Caspase12 are potentially novel biomarkers for oral squamous cell carcinoma development and progression","volume":"7","author":"Wang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ejmech.2023.115683_bib59","first-page":"1","article-title":"Intracellular NOD-like receptors in innate immunity, infection and disease","volume":"10","author":"Franchi","year":"2008","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.ejmech.2023.115683_bib60","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1128\/IAI.01459-13","article-title":"The Nod1, Nod2, and Rip2 Axis contributes to host immune defense against intracellular acinetobacter baumannii infection","volume":"82","author":"Bist","year":"2014","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2023.115683_bib61","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/416194a","article-title":"RICK\/Rip2\/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems","volume":"416","author":"Kobayashi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115683_bib62","doi-asserted-by":"crossref","unstructured":"Y. Ogawa, W. Calhoun, The role of leukotrienes in airway inflammation, J. Allergy Clin. Immunol. 118 (2006) 789\u2013798. https:\/\/doi.org\/10\/cxtbk4.","DOI":"10.1016\/j.jaci.2006.08.009"},{"key":"10.1016\/j.ejmech.2023.115683_bib63","doi-asserted-by":"crossref","unstructured":"J. Hu, H. Kang, C. Liu, P. Hu, M. Yang, F. Zhou, Regulatory T cells could improve intestinal barrier dysfunction in heatstroke, Inflammation. 42 (2019) 1228\u20131238. https:\/\/doi.org\/10\/grz69pp. .","DOI":"10.1007\/s10753-019-00983-6"},{"key":"10.1016\/j.ejmech.2023.115683_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/498980","article-title":"Targeting Toll-like receptors for treatment of SLE","author":"Horton","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2023.115683_bib65","doi-asserted-by":"crossref","unstructured":"A. Couturier-Maillard, T. Secher, A. Rehman, S. Normand, A. De Arcangelis, R. Haesler, L. Huot, T. Grandjean, A. Bressenot, A. Delanoye-Crespin, O. Gaillot, S. Schreiber, Y. Lemoine, B. Ryffel, D. Hot, G. N\u00f9\u00f1ez, G. Chen, P. Rosenstiel, M. Chamaillard, NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer, J. Clin. Invest. (2013) JCI62236. https:\/\/doi.org\/10\/gbch9m.","DOI":"10.1172\/JCI62236"},{"key":"10.1016\/j.ejmech.2023.115683_bib66","first-page":"37","article-title":"Emerging roles for RIPK1 and RIPK3 in pathogen-induced cell death and host immunity","volume":"403","author":"Saleh","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ejmech.2023.115683_bib67","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/JLB.4HI0118-017RR","article-title":"Frontline Science: RIP2 promotes house dust mite-induced allergic airway inflammation","volume":"104","author":"Miller","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2023.115683_bib68","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.immuni.2013.10.013","article-title":"The protein ATG16L1 suppresses inflammatory cytokines induced by the intracellular sensors Nod1 and Nod2 in an autophagy-independent manner","volume":"39","author":"Sorbara","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2023.115683_bib69","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.phrs.2018.10.016","article-title":"Gene silencing of receptor-interacting protein 2 protects against cigarette smoke-induced acute lung injury","volume":"139","author":"Dong","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115683_bib70","doi-asserted-by":"crossref","first-page":"11645","DOI":"10.1523\/JNEUROSCI.4181-05.2005","article-title":"Dysregulation of receptor interacting protein-2 and caspase recruitment domain only protein mediates aberrant caspase-1 activation in huntington's disease","volume":"25","author":"Wang","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115683_bib71","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12974-020-02015-9","article-title":"NOD1\/RIP2 signalling enhances the microglia-driven inflammatory response and undergoes crosstalk with inflammatory cytokines to exacerbate brain damage following intracerebral haemorrhage in mice","volume":"17","author":"Wang","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2023.115683_bib72","unstructured":"L.P. Rowland, N.A. Shneider, Amyotrophic lateral sclerosis, N. Engl. J. Med. (2001). https:\/\/doi.org\/10\/c8kwc5."},{"key":"10.1016\/j.ejmech.2023.115683_bib73","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/mcne.2002.1136","article-title":"Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS","volume":"20","author":"Gu\u00e9gan","year":"2002","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115683_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110128","article-title":"RIPK2 as a promising druggable target for autoimmune diseases","volume":"118","author":"Zhao","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2023.115683_bib75","doi-asserted-by":"crossref","unstructured":"Y.-G. Chen, Research progress in the pathogenesis of alzheimer's disease, Chin. Med. J. 131 (2018) 1618\u20131624. https:\/\/doi.org\/10\/gdrqqx.","DOI":"10.4103\/0366-6999.235112"},{"key":"10.1016\/j.ejmech.2023.115683_bib76","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1021\/acschemneuro.8b00435","article-title":"Genetic analyses of alzheimer's disease in China: achievements and perspectives","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115683_bib77","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1523\/JNEUROSCI.2824-07.2008","article-title":"The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy","volume":"28","author":"Mocanu","year":"2008","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115683_bib78","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.4103\/0366-6999.235112","article-title":"Research progress in the pathogenesis of alzheimer's disease","volume":"131","author":"Chen","year":"2018","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejmech.2023.115683_bib97","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1038\/ncomms7442","article-title":"A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production","volume":"6","author":"Nachbur","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115683_bib98","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1021\/acs.jmedchem.6b00211","article-title":"The identification and pharmacological characterization of 6-(tert -butylsulfonyl)- N -(5-fluoro-1 H -indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase","volume":"59","author":"Haile","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib99","unstructured":"T. Fan, Y. Ji, D. Chen, X. Peng, J. Ai, B. Xiong, Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors, J. Enzym. Inhib. Med. Chem. ((n.d.))."},{"key":"10.1016\/j.ejmech.2023.115683_bib79","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1021\/acs.jmedchem.9b00575","article-title":"Discovery of a first-in-class receptor interacting protein 2 (RIP2) kinase specific clinical candidate, 2-((4-(benzo[ d ]thiazol-5-ylamino)-6-(tert -butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate, for the treatment of inflammatory diseases","volume":"62","author":"Haile","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib80","doi-asserted-by":"crossref","unstructured":"T. Goncharov, S. Hedayati, M.M. Mulvihill, A. Izrael-Tomasevic, K. Zobel, S. Jeet, A.V. Fedorova, C. Eidenschenk, J. deVoss, K. Yu, A.S. Shaw, D.S. Kirkpatrick, W.J. Fairbrother, K. Deshayes, D. Vucic, Disruption of XIAP-RIP2 association blocks NOD2-mediated inflammatory signaling, Mol. Cell. 69 (2018) 551-565.e7. https:\/\/doi.org\/10\/gc3k9w.","DOI":"10.1016\/j.molcel.2018.01.016"},{"key":"10.1016\/j.ejmech.2023.115683_bib81","doi-asserted-by":"crossref","unstructured":"M. Wang, X. Ye, J. Hu, Q. Zhao, B. Lv, W. Ma, W. Wang, H. Yin, Q. Hao, C. Zhou, T. Zhang, W. Wu, Y. Wang, M. Zhou, C. Zhang, G. Cui, NOD1\/RIP2 signalling enhances the microglia-driven inflammatory response and undergoes crosstalk with inflammatory cytokines to exacerbate brain damage following intracerebral haemorrhage in mice, J. Neuroinflammation 17 (2020) 364. https:\/\/doi.org\/10\/gqtg9c.","DOI":"10.1186\/s12974-020-02015-9"},{"key":"10.1016\/j.ejmech.2023.115683_bib82","doi-asserted-by":"crossref","unstructured":"G. Wang, C. Zhang, F. Jiang, M. Zhao, S. Xie, X. Liu, NOD2-RIP2 signaling alleviates microglial ROS damage and pyroptosis via ULK1-mediated autophagy during Streptococcus pneumonia infection, Neurosci. Lett. 783 (2022) 136743. https:\/\/doi.org\/10\/gqtg9b.","DOI":"10.1016\/j.neulet.2022.136743"},{"key":"10.1016\/j.ejmech.2023.115683_bib83","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/acsmedchemlett.7b00258","article-title":"Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases","volume":"8","author":"He","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115683_bib84","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1038\/ncomms7442","article-title":"A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production","volume":"6","author":"Nachbur","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115683_bib85","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/1535-7163.MCT-19-0903","article-title":"Gefitinib inhibits invasion and metastasis of osteosarcoma via inhibition of macrophage receptor interacting serine-threonine kinase 2","volume":"19","author":"Maloney","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115683_bib86","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/molecules23020453","article-title":"Identification of novel protein kinase receptor type 2 inhibitors using pharmacophore and structure-based virtual screening","volume":"23","author":"Cruz","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115683_bib87","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1016\/j.bmc.2015.09.038","article-title":"Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: foundations for understanding inhibitor selectivity","volume":"23","author":"Charnley","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib88","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acsmedchemlett.9b00141","article-title":"Discovery of pyrazolocarboxamides as potent and selective receptor interacting protein 2 (RIP2) kinase inhibitors","volume":"10","author":"Haffner","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115683_bib89","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acsmedchemlett.9b00141","article-title":"Discovery of pyrazolocarboxamides as potent and selective receptor interacting protein 2 (RIP2) kinase inhibitors","volume":"10","author":"Haffner","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115683_bib90","doi-asserted-by":"crossref","unstructured":"R. Ben-Levy, I.A. Leighton, Y.N. Doza, P. Attwood, N. Morrice, C.J. Marshall, P. Cohen, Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2, EMBO J.. 14 (1995) 5920\u20135930. https:\/\/doi.org\/10\/gqtg86.","DOI":"10.1002\/j.1460-2075.1995.tb00280.x"},{"key":"10.1016\/j.ejmech.2023.115683_bib100","doi-asserted-by":"crossref","unstructured":"K. Yanase, S. Tsukahara, S. Asada, E. Ishikawa, Y. Imai, Y. Sugimoto, Gefitinib reverses breast cancer resistance protein\u2013mediated drug resistance, Mol. Cancer Therapeut. 3 (2004) 1119\u20131125. https:\/\/doi.org\/10\/grz7md.","DOI":"10.1158\/1535-7163.1119.3.9"},{"key":"10.1016\/j.ejmech.2023.115683_bib101","doi-asserted-by":"crossref","unstructured":"C. Maloney, M.P. Kallis, M. Edelman, C. Tzanavaris, M. Lesser, S.Z. Soffer, M. Symons, B.M. Steinberg, Gefitinib inhibits invasion and metastasis of osteosarcoma via inhibition of macrophage receptor interacting serine-threonine kinase 2, Mol. Cancer Therapeut. 19 (2020) 1340\u20131350. https:\/\/doi.org\/10\/gqtg89.","DOI":"10.1158\/1535-7163.MCT-19-0903"},{"key":"10.1016\/j.ejmech.2023.115683_bib102","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"For the north-east Japan study group, gefitinib alone versus gefitinib plus chemotherapy for non\u2013small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115683_bib103","doi-asserted-by":"crossref","unstructured":"Y. Hosomi, S. Morita, S. Sugawara, T. Kato, T. Fukuhara, A. Gemma, K. Takahashi, Y. Fujita, T. Harada, K. Minato, K. Takamura, K. Hagiwara, K. Kobayashi, T. Nukiwa, A. Inoue, North-east Japan study group, gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 38 (2020) 115\u2013123. https:\/\/doi.org\/10\/ghxd6t.","DOI":"10.1200\/JCO.19.01488"},{"key":"10.1016\/j.ejmech.2023.115683_bib104","doi-asserted-by":"crossref","unstructured":"V. Noronha, V.M. Patil, A. Joshi, N. Menon, A. Chougule, A. Mahajan, A. Janu, N. Purandare, R. Kumar, S. More, S. Goud, N. Kadam, N. Daware, A. Bhattacharjee, S. Shah, A. Yadav, V. Trivedi, V. Behel, A. Dutt, S.D. Banavali, K. Prabhash, Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 38 (2020) 124\u2013136. https:\/\/doi.org\/10\/gf8vr5.","DOI":"10.1200\/JCO.19.01154"},{"key":"10.1016\/j.ejmech.2023.115683_bib105","doi-asserted-by":"crossref","unstructured":"C.R. Culy, D. Faulds, Gefitinib, Drugs. 62 (2002) 2237\u20132248; discussion 2249-2250. https:\/\/doi.org\/10\/bk568x.","DOI":"10.2165\/00003495-200262150-00008"},{"key":"10.1016\/j.ejmech.2023.115683_bib119","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/0008-5472.379.65.2","article-title":"Cellular targets of gefitinib","volume":"65","author":"Brehmer","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115683_bib91","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899372","article-title":"Small molecule inhibitors reveal an indispensable scaffolding role of RIPK 2 in NOD 2 signaling","volume":"37","author":"Hrdinka","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2023.115683_bib92","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/acs.jmedchem.2c00604","article-title":"Discovery of potent and selective receptor-interacting serine\/threonine protein kinase 2 (RIPK2) inhibitors for the treatment of inflammatory bowel diseases (IBDs)","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib93","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib94","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bmcl.2018.01.044","article-title":"Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors","volume":"28","author":"Suebsuwong","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115683_bib106","doi-asserted-by":"crossref","unstructured":"J. Cortes, J. Apperley, E. Lomaia, B. Moiraghi, M. Undurraga Sutton, C. Pavlovsky, C. Chuah, T. Sacha, J.H. Lipton, C.A. Schiffer, J. McCloskey, A. Hochhaus, P. Rousselot, G. Rosti, H. de Lavallade, A. Turkina, C. Rojas, C.K. Arthur, L. Maness, M. Talpaz, M. Mauro, T. Hall, V. Lu, S. Srivastava, M. Deininger, Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial, Blood. 138 (2021) 2042\u20132050. https:\/\/doi.org\/10\/gpk4hj.","DOI":"10.1182\/blood.2021012082"},{"key":"10.1016\/j.ejmech.2023.115683_bib107","doi-asserted-by":"crossref","unstructured":"J.E. Cortes, D.-W. Kim, J. Pinilla-Ibarz, P.D. le Coutre, R. Paquette, C. Chuah, F.E. Nicolini, J.F. Apperley, H.J. Khoury, M. Talpaz, D.J. DeAngelo, E. Abruzzese, D. Rea, M. Baccarani, M.C. M\u00fcller, C. Gambacorti-Passerini, S. Lustgarten, V.M. Rivera, F.G. Haluska, F. Guilhot, M.W. Deininger, A. Hochhaus, T.P. Hughes, N.P. Shah, H.M. Kantarjian, Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial, Blood. 132 (2018) 393\u2013404. https:\/\/doi.org\/10\/gdzbxm.","DOI":"10.1182\/blood-2016-09-739086"},{"key":"10.1016\/j.ejmech.2023.115683_bib108","doi-asserted-by":"crossref","unstructured":"G. Martinelli, C. Papayannidis, A. Piciocchi, V. Robustelli, S. Soverini, C. Terragna, G. Marconi, R.M. Lemoli, F. Guolo, A. Fornaro, M. Lunghi, P. de Fabritiis, A. Candoni, C. Selleri, F. Simonetti, M. Bocchia, A. Vitale, L. Frison, A. Tedeschi, A. Cuneo, M. Bonifacio, M.P. Martelli, S. D'Ardia, S. Trappolini, P. Tosi, P. Galieni, F. Fabbiano, M.C. Abbenante, M. Granier, Z. Zhu, M. Wang, C. Sartor, S. Paolini, M. Cavo, R. Fo\u00e0, P. Fazi, M. Vignetti, M. Baccarani, INCB84344-201: ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia, Blood Adv. 6 (2022) 1742\u20131753. https:\/\/doi.org\/10\/gqtg84.","DOI":"10.1182\/bloodadvances.2021004821"},{"key":"10.1016\/j.ejmech.2023.115683_bib109","doi-asserted-by":"crossref","unstructured":"T. O'Hare, W.C. Shakespeare, X. Zhu, C.A. Eide, V.M. Rivera, F. Wang, L.T. Adrian, T. Zhou, W.-S. Huang, Q. Xu, C.A. Metcalf, J.W. Tyner, M.M. Loriaux, A.S. Corbin, S. Wardwell, Y. Ning, J.A. Keats, Y. Wang, R. Sundaramoorthi, M. Thomas, D. Zhou, J. Snodgrass, L. Commodore, T.K. Sawyer, D.C. Dalgarno, M.W.N. Deininger, B.J. Druker, T. Clackson, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance, Cancer Cell. 16 (2009) 401\u2013412. https:\/\/doi.org\/10\/bdn4nm.","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"10.1016\/j.ejmech.2023.115683_bib110","doi-asserted-by":"crossref","unstructured":"P. Zeng, A. Schmaier, Ponatinib and other CML tyrosine kinase inhibitors in thrombosis, Int. J. Mol. Sci. 21 (2020) E6556. https:\/\/doi.org\/10\/gpvt6h.","DOI":"10.3390\/ijms21186556"},{"key":"10.1016\/j.ejmech.2023.115683_bib111","doi-asserted-by":"crossref","unstructured":"A.P. Singh, P. Umbarkar, S. Tousif, H. Lal, Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib, Int. J. Cardiol. 316 (2020) 214\u2013221. https:\/\/doi.org\/10\/gqtg85.","DOI":"10.1016\/j.ijcard.2020.05.077"},{"key":"10.1016\/j.ejmech.2023.115683_bib95","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.chembiol.2015.07.017","article-title":"Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors","volume":"22","author":"Canning","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115683_bib112","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115683_bib113","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.1021\/acs.jmedchem.1c01118","article-title":"Optimization of a series of RIPK2 PROTACs","volume":"64","author":"Miah","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115683_bib96","doi-asserted-by":"crossref","unstructured":"R. Wen, J. Lv, P. Jia, W. Yang, N. Wang, X. Wu, Z. Xue, Y. Liu, The protective effects of natural product tunicatachalcone against neuroinflammation via targeting RIPK2 in microglia BV-2 cells stimulated by LPS, Bioorg. Med. Chem. 69 (2022) 116916. https:\/\/doi.org\/10\/gqtg88.","DOI":"10.1016\/j.bmc.2022.116916"},{"key":"10.1016\/j.ejmech.2023.115683_bib114","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1172\/JCI124617","article-title":"The balance of power: innate lymphoid cells in tissue inflammation and repair","volume":"129","author":"Castellanos","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.115683_bib115","article-title":"Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonists","volume":"6","author":"Chen","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115683_bib116","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ibd.20332","article-title":"Mucosal NOD2 expression and NF-\u03baB activation in pediatric Crohn\u02bcs disease","volume":"14","author":"Stronati","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejmech.2023.115683_bib117","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.3390\/ijms15069594","article-title":"NOD-like receptors in intestinal homeostasis and epithelial tissue repair","volume":"15","author":"Parlato","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115683_bib118","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.molmed.2018.01.004","article-title":"Inflammasome, inflammation, and tissue homeostasis","volume":"24","author":"Rathinam","year":"2018","journal-title":"Trends Mol. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:59:16Z","timestamp":1759330756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423006499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":119,"alternative-id":["S0223523423006499"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115683","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RIPK2 inhibitors for disease therapy: Current status and perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115683"}}